Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Infectious diseases 13

Infectious Diseases

recent-pharma-news-and-updates-for-novartis-gsk-exact-sciences-eqrx

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone’s deal for checkpoint inhibitors

Novartis taps Molecular Partners for a novel approach to combat COVID-19 Novartis is spending USD 69 million upfront on a pair of experimental drugs from Molecular Partners. The pact is for MP0420 and MP0423, two antivirals out of the biotech’s so-called DARPin tech, which Molecular Partners says that it has multi-specific target binding with the potential to avert viral escape via mutations, the prospect for subcutaneous administration, the long half-life for sustained activity, the potential to avoid cold storage and typically high-yield, highly scalable production in bacterial fermenters. MP0420 is the furthest along, with phase 1 scheduled for next month ...

Explore More...

Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

Notizia

transthyretin amyloidosis

Notizia

Cancer

SNIPPET

Entasis

AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal

Therapeutics

The Business Cocktail(Therapeutics)

parkinson's

Parkinson’s and tuberculosis shares a common protein that could provide better drugs for both

COMMON COLD

Potential cure for Common cold

transthyretin amyloidosis

Notizia

Gilead Sciences Introduces Sovaldi: A Potent Hepatitis C Treatment

BioGen

Business Cocktail

transthyretin amyloidosis

Notizia

BioGen

Notizia

transthyretin amyloidosis

Notizia

transthyretin amyloidosis

Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln’s anti-malarial drug

Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly